ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.

E Gabriela Chiorean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.